Allen B. King - Concepedia

Author

Allen B. King

Also Known As

A B King, A. B. KING, A. B. King, A. King, A.B. King, ALLEN B. KING, Allen B King, Allen B. King, Allen Bennett King, Allen King

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Diabetes Care Center Novo Nordisk (Denmark)University of California, San Francisco Connolly Hospital Blanchardstown Baylor University Medical Center

About

Allen B. King is an author at Diabetes Care Center specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	757
2	Health Sciences	3	3	176
3	Public Health	3	3	112
4	Education	1	1	14
5	Social Sciences	1	1	19

Allen B. King

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Alan J. Garber, Allen B. King, Stefano Del Prato, The Lancet Diabetes ManagementInsulin DegludecDiabetesInsulin ManagementType 2	2012	323
A Bolus Calculator Is an Effective Means of Controlling Postprandial Glycemia in Patients on Insulin Pump Therapy Todd M. Gross, David Kayne, Allen B. King, Diabetes Technology & Therapeutics Metabolic SyndromeDiabetes ManagementBody CompositionHealth PolicyInsulin Management	2003	143
Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes Irl B. Hirsch, Bruce W. Bode, J.P. Courrèges, Diabetes Care	2012	75
Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal‐only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14‐week follow‐up data from PREDICTIVE™ Anne Dornhorst, H.‐J. Lüddeke, Christoph Koenen, Diabetes Obesity and Metabolism	2007	56
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs Allen B. King, Poon Drug Healthcare and Patient Safety	2010	55
Personal and mediated health counseling for sustained dietary reduction of hypercholesterolemia Michael Crouch, James F. Sallis, John W. Farquhar, Preventive Medicine NutritionCounselingFamily MedicineSustained Dietary ReductionHealth Policy	1986	53
A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at near Normal Glucose Control: Bolus Dosing Allen B. King, Dana Armstrong Journal of Diabetes Science and Technology	2007	52
Once‐daily insulin detemir is comparable to once‐daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double‐blind, randomized, crossover study Allen B. King Diabetes Obesity and Metabolism	2008	46
Lipid Response to Pioglitazone in Diabetic Patients: Clinical Observations from a Retrospective Chart Review Allen B. King, Dana Armstrong Diabetes Technology & Therapeutics Diabetic PatientsHyperlipidemiaObesityMetabolic SyndromeConcurrent Statin Treatment	2002	36
Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy Priscilla Hollander, Allen B. King, Stefano Del Prato, Diabetes Obesity and Metabolism Metabolic SyndromeNutritionDiabetes ManagementBasal‐bolus Insulin TherapyInsulin Degludec	2014	34

Page 1